Frontiers in Pharmacology (Aug 2024)
Corrigendum: Proteasome inhibitor YSY01A abrogates constitutive STAT3 signaling via down-regulation of Gp130 and JAK2 in human A549 lung cancer cells
- Wei Huang,
- Wei Huang,
- Xia Yuan,
- Ting Sun,
- Shujie Fan,
- Jun Wang,
- Quan Zhou,
- Wei Guo,
- Fuxiang Ran,
- Zemei Ge,
- Huayu Yang,
- Runtao Li,
- Jingrong Cui
Affiliations
- Wei Huang
- Department of Pharmacology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing, China
- Wei Huang
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China
- Xia Yuan
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China
- Ting Sun
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China
- Shujie Fan
- Department of Pharmacology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing, China
- Jun Wang
- Department of Pharmacology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing, China
- Quan Zhou
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China
- Wei Guo
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China
- Fuxiang Ran
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China
- Zemei Ge
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University, Beijing, China
- Huayu Yang
- Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Runtao Li
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University, Beijing, China
- Jingrong Cui
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China
- DOI
- https://doi.org/10.3389/fphar.2024.1418274
- Journal volume & issue
-
Vol. 15
Abstract
No abstracts available.Keywords
